

## PUBLICATIONS

1. Foster H, Hooper M, Imann S H, Lovett G S, Nicholson J, Swain C J, Sweetman A J, Weetman D F. (1983) Biological Activities of Isatogens Brit. J. Pharm., 79, 273.
2. Baker R, Bhaskar Rao V, Ravenscroft P D, Swain C J. (1983) Oxidation of Trimethylsilyl ethers. Synthesis, 572 (1983).
3. Baker R, Bayes R H O, Broom D M P, Devlin J A, Swain C J. (1983) The Chemistry of Spiroacetals: Enantiospecific synthesis of the spiroacetal unit of Milbemycin  $\beta_3$ . J. Chem. Soc. Chem. Commun, 829.
4. Baker R, Ravenscroft P D, Swain C J. (1984) The total synthesis of Ancistrofuran. J. Chem. Soc. Chem. Commun. 74.
5. Baker R, Gibson C L, Swain C J., Tapolsczay D J. (1984) Synthetic studies on Paniculides. J. Chem. Soc. Chem. Commun. 619.
6. Baker R, O'Mahony M J, Swain C J. (1984) The total synthesis of Wintermoth Pheromone. J. Chem. Res. 190.
7. Baker R, Head J C, Swain C J. (1985) The Chemistry of Spiroacetals: Enantiospecific Synthesis of the spiroacetal unit of Avermectin  $\beta_{1b}$  and  $\beta_{2b}$ . J. Chem. Soc. Chem. Commun. 309.
8. Baker R, Swain C J, Head J. (1985) Recent Advances in the Chemistry of Insect Control. Ed. N.F. Jones, Pub. The Royal Society of Chemistry. p.245.
9. Baker R, Gibson C L, Swain C J, Tapolczay D J. (1985) Synthetic studies on the Paniculides. J. Chem Soc. Perk I, 1590.
10. Baker R, Cotterell I F, Ravenscroft P D, Swain C J. (1985) The total synthesis of Ancistrofuran. J. Chem. Soc. Perk I, 2463.
11. Baker R, O'Mahony M J, Swain C J. (1985) The total synthesis of (+) Milbemycin  $\beta_3$ . J. Chem. Soc. Chem. Commun., 1326.
12. Baker R, Head J C, Swain C J. (1985) Chemistry of Spiroacetals, Enantiospecific synthesis of the spiroacetal units of milbemycins a7 and a8. J. Chem. Soc. Chem. Commun., 874.
13. Hooper M, Adams D B, Swain C J, Raper E S, Stoddart B. (1986) Isatogens: X-ray crystal structure. J. Chem. Soc. Perk. I, 1005.
14. Swain C J, Baker R, O'Mahony. (1986) A formal synthesis of Milbemycin  $\beta_3$ . Tetrahedron Lett. 27, 3059.
15. Baker R, Boyes R H O, Broom D M P, O'Mahony M J, Swain C J. (1987) Enantiospecific synthesis of the spiroacetal unit of Milbemycin  $\beta_3$ . J. Chem. Soc. Perkin Trans 1, 1613.
16. Baker R, O'Mahony M J, Swain C J. (1987) The total synthesis of (+) Milbemycin  $\beta_3$ . J. Chem. Soc. Perkin Trans. 1, 1623.
17. Baker R, Head J C, Swain C J. (1988) Synthesis of spiroacetals. J. Chem. Soc. Perkin Trans 1., 85.
18. Castro J L, Baker R, Swain C J. (1988) Directed Aldol Chemistry. Tet. Lett. 29 (18) 2247.
19. Watling K J, Aspley S, Swain C J, Saunders J. (1988) Radioligand binding assay for 5-HT<sub>3</sub> antagonists. Eur. J. Pharmac. 149, 397.
20. Baker R, Boyes A L, Swain C J. (1989) The total synthesis of Talaromycins A,B,C and E. Tet. Lett, 30 (8) 985.

21. Baker R, Swain C J. Ivermectin - A drug for all seasons. *Chem. in Brit.*, 692.
22. Watgen F, Baker R, Engelstoff M, Herbert R, MacLeod A, Knight A, Merchant K, Moseley J, Saunders J, Swain C J, Wong E, Springer J P. (1989) Novel Benzodiazepine Receptor Partial Agonists: Oxadiazolyimidazobenzodiazepines. *J. Med. Chem.* 32, 2282.
23. Swain C J, Kneen C, Baker R. (1990) Synthesis of Indole Oxazolines, Potent 5-HT<sub>3</sub> antagonists. *Tet. Lett.* 31, 2445.
24. Baker R, Boyes A L, Swain C J. (1990) Synthesis of Talaromycins A, B, C and E. *J. Chem. Soc. Perkin Trans 1.*, 1415.
25. McKernan R M, Gillard N P, Quirk K, Kneen C O, Stevenson G I, Swain C J, Ragan C I. (1990) Purification of the 5-HT<sub>3</sub> receptor from NCB20 cells. *J. Biol. Chem.* 265 (23), 13572.
26. Swain C J, Kneen C, Herbert R, Baker R. (1990) Synthesis of Indole Oxazolines: Novel 5-HT<sub>3</sub> antagonists. *J. Chem. Soc. Perkin Trans 1* 3183.
27. Swain C J, Baker R, Kneen C, Moseley J, Saunders J, Seward E M, Stevenson G, Beer M, Stanton J, Watling K. (1991) Novel 5-HT<sub>3</sub> Antagonists. *Indole Oxadiazoles*. *J. Med. Chem.* 34, 140.
28. Booth S E, Jenkins P R, Swain C J. (1991) The Synthesis of Bicyclic and Tricyclic Ring Systems by Radical Cyclisation Reactions of Oxime ethers. *J. Chem Soc. Chem. Commun.* 1248.
29. Tattersall D, Newberry N, Beer M, Rigby M, Gilbert M, Maquire J, Mudunotuwa N, Duchonowski M, McKnight A, Swain C J, Kneen C, Dourish C. (1992) L-683,877: Pharmacological Profile of a Novel 5-HT<sub>3</sub> Receptor Antagonist. *Drug Development Research*, 25, 25, 17.
30. Swain C J, Baker R, Kneen C, Herbert R, Moseley J, Saunders J, Seward E M, Stevenson G I, Beer M, Stanton J, Watling K, Ball R G. (1992) Novel 5-HT<sub>3</sub> Antagonists: Indol-3-ylspiro(azabicycloalkane-3,51(41H)-oxazoles). *J Med. Chem.*, 35, 1019.
31. Cascieri M A, Ber E, Tung M F, Sadowski S, Bansal S, Swain C J, Seward E M, Frances B, Burns D, Strader C D. (1992) Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor. *Molecular Pharmacology*, 42, 458-463.
32. Jenkins P, Symons M C R, Booth S E, Swain C J. (1992) Why is a vinyl anion configurationally stable but a vinyl radical configurationally unstable. *Tet. Lett.*, 33, 3543.
33. Rajagopal S, Diksic M, Francis B, Swain C J, Burns H D. (1992) Synthesis of a <sup>11</sup>C-labeled novel, quinuclidine based ligand for the 5-HT<sub>3</sub> receptor. *Applied Radiation and Isotopes*, 43, 1369-1373,
34. Francis B E, Swain C J, Sabin V, Burns H D. Radioiodinated L-703,606:A Potent Selective Antagonist to the human NK1 Receptor. *Appl. Radiat. Isot.*
35. Booth S E, Jenkins P R, Swain C J. (1993) A novel Ring expansion reaction in the reduction of Benzylic Methoxyamines with Lithium Aluminium Hydride. *J. Chem. Soc. Chem. Commun.*, 147.
36. Cascieri M A, Fong T M, Yu H, Bansai A, Swain C J, Strader C D. (1993). Amino-aromatic interaction between histidine 197 of the NK1 receptor and CP 96345. *Nature*, 362, 350.
37. Seward E M, Swain C J, Merchant K J, Owen S N, Sabin V, Cascieri M A, Sadowski S, Strader C D, Baker R. (1993) Quinuclidine Based NK1 antagonists 1: 3-Benzyloxy-1-azabicyclo[2.2.2]octanes. *Bioorganic and Med. Chem. Lett.*, 3, (6), 1361.
38. MacLeod A M, Merchant K J, Cascieri M A, Shadowski S, Ber E, Swain C J, Baker R. (1993) N-Acyl-L-Tryptophan Benzyl Esters: Potent Substance P antagonists. *J. Med. Chem.* 36, 2044.
39. Swain C J, Seward E M, Sabin V, Owen S, Baker R, Cascieri M A, Sadowski S, Strader C,

- Ball R G. (1993) Quinuclidine Based NK1 Antagonists 2: Determination of the Absolute Stereochemical Requirements, *Bioorganic and Med. Chem. Lett.* 3 (8), 1703.
40. Fong T M, Yu H, Cascieri M A, Underwood D, Swain C J, Strader C D. (1994) The role of the Histidine 265 in Antagonist Binding to the NK1 Receptor. *J. Biol. Chem.* 269 (4), 2728.
41. Cascieri M A, MacLeod A M, Underwood D, Shiao L, Ber E, Sadowski S, Yu H, Merchant K J, Swain C J, Strader C D, Fong T M. (1994) Characterization of the Interaction of N-Acyl-L-Tryptophan Benzyl Ester Neurokinin Antagonists with the human NK1 receptor. *J. Biol. Chem.* 269 (9), 6587.
42. MacLeod A M, Merchant K J, Brookfield F, Kelleher F, Stevenson G, Owens A P, Swain C J, Cascieri M A, Sadowski S, Ber E, Strader C D, Macintyre D E, Metzger J M, Ball R G, Baker R. (1994) Identification of L-Tryptophan Derivatives with Potent and Selective Activity at the NK1 receptor. *J. Med. Chem.* 37, 1269.
43. Fong T M, Yu H, Cascieri M A, Underwood D, Swain C J, Strader C D. (1994) Interaction of Glutamine 165 in the fourth Transmembrane Segment of the human NK1 Receptor with Quinuclidine Receptor with Quinuclidine Antagonists. *J. Biol. Chem.* 269 (21) 14957.
44. Williams B J, Teall M, McKenna J, Harrison T, Swain C J, Cascieri M A, Sadowski S, Strader C D, Baker R. (1994) Acyclic NK1 Antagonists: 2-Benzhydryl-2-aminoethyl ethers. *Bioorg. and Med. Chem. Lett.* 4, (16), 1903.
45. Swain C J, Cascieri M A, Owens A, Saari W, Sadowski S, Strader C, Teall M, Van Niel M B, Williams B J. (1994) Acyclic NK1 antagonists: Replacement for the benzhydryl group. *Bioorganic and Med. Chem. Lett.* 4, (18), 2161.
46. Harrison T, Williams B J, Swain C J, Ball R G. (1994) Piperidine-Ether Based hNK1 Antagonists 1: Determination of the Relative and Absolute Stereochemical Requirements. *Bioorganic and Med. Chem. Lett.* 4 (21), 2545.
47. Harrison T, Williams B J, Swain C J. (1994) Gem-Disubstituted Amino-ether Based Substance P antagonists. *Bioorganic and Med. Chem. Lett.* 4 (23), 2733.
48. Jenkins P R, Booth S E, Swain C J, Sweeny J B. (1994) Intramolecular Addition of Vinyl and Aryl radicals to Oxime ethers in the synthesis of Five, Six and Seven-membered Ring Systems. *J. Chem. Soc. Perkin Trans. 1.* 3499.
49. Longmore J, Swain C J, Hill R G. (1995) Neurokinin Receptors. *Drug News and Perspectives.* 8 (1), 5.
50. Cascieri M A, Shiao L, Mills S G, MacCoss M, Swain C J, Yu H, Ber E, Sadowski S, Wu M T, Strader C D, Fong T M. (1995) Characterisation of the Interaction of Diacylpiperazine Antagonists with the human NK1 receptor: Identification of a Common Binding site for structurally Dissimilar Antagonists. *Mol. Pharm.* 47, 660.
51. Swain C J., Fong T M, Haworth K, Owen S N, Seward E M. (1995) Quinuclidine based NK1 antagonists the role of the benzhydryl. *Bioorganic and Med. Chem. Lett.* 5(12), 1261.
52. Fong T M, Ruey-Ruey C, Huang H Y, Swain C J, Underwood D, Cascieri M A, Strader C D. (1995) Mutational analysis of neurokinin receptor function. *Cam. J. Physiol. Pharmacol.* 73, 860.
53. Owens A P, Williams B J, Harrison T, Swain C J, Baker R, Sadowski S, Cascieri M A. (1995) Phenyl-Glycinol Based NK1 receptor antagonists-Towards the minimum Pharmacophore, *Bioorganic and Med. Chem. Lett.* 5 (22), 2761.
54. Swain C J, Seward E M, Cascieri M A, Fong T M, Herbert R, MacIntyre D E, Merchant K J, Owen S, Owens A P, Sabin V, Teall M, Van Niel M B, Williams B J, Sadowski S, Strader C D, Ball R G, Baker R. (1995) Identification of a series of 3-Benzyl-oxy-1-azabicyclo[2.2.2]octane human NK1 antagonists. *J. Med. Chem.* 38, 4793 .

55. Fong T M, Yu H, Huang R-R, Swain C J, Undewrwood D, Cascieri M A, Strader C D, (1995) Mutational analysis of neurokinin receptor function, *Can. J. Physiol. Pharmacol.* 73, 860
56. Swain C J, (1996) Neurokinin Receptor Antagonists, *Expert Opinion on Therapeutic Patents*, 6 (4) 367.
57. Swain C J, (1996) Neurokinin Receptor Antagonists, *Drug Discovery Today*, 1 (6)
58. Ladduwahetty T, Swain C J, Keown L, Seward E M, Haworth K, Owen S, Chambers M, Baker R, Cascieri M A, Hargreaves R J, Iversen L L, MacIntyre D E, Metzger J M, Sadowski S, Shephard S, Strader C D, Tattersall F D, (1996) L-741,671: A potent orally active human NK1 antagonist, *J. Med. Chem.* 39, 2907
59. Swain C J, Hargreaves R, J (1996) Neurokinin Receptor Antagonists, *Annual Reports in Medicinal Chemistry*, 31, Chapter 12, 111
60. Fong T M, Yu H, Huang R-R, Cascieri M A, Swain C J, (1996) Relative Contribution of Polar Interactions and Conformational Compatibility to the binding of Neurokinin-1 Receptor Antagonists, *Molecular Pharmacology*, 50, 1605
61. Tattersall F D, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod A M, Ladduwahetty T, Keone L, Swain C, Baker R, Cascieri M, Ber E, Metzger J, MacIntyre D E, Hill R, Hargreaves R, (1996) Tachykinin NK1 Receptor Antagonists act centrally to inhibit Emesis Induced by the chemotherapeutic agent Cisplatin in Ferrets *Neuropharmacology*, 35, 8, 1121.
62. Rupniak N M J, Tattersall F D, Williams A R, Rycroft W, Carlson E J, Cascieri M, Sadowski S, Ber E, Hale J, Mills S, MacCoss M, Seward E, Huscroft I, Owen S, Swain C J, Hill R G, Hargreaves R J, (1997) In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists, *Eur J Pharmacol.* 326, 201.
63. Swain C J, Williams B J, Baker R, Cascieri M A 1, Chicchi G 1, Forrest M 2, Herbert R, Keown L, Ladduwahetty T, Luell S, MacIntyre D E, Metzger J, Morton S, Owens A P, Sadowski S 1 and Watt A P. (1997) 3-Benzyloxy-2-Phenylpiperidine NK1 antagonists: The influence of alpha methyl substitution. *Bioorganic and Medchem Letters*, 7 (23), 2959.
64. Owens A P, Harrison T, Moseley J D, Swain C J, Sadowski S 1 and Cascieri M A. (1998) High Affinity Phenylglycinol-Based NK1 Antagonists. *Bioorganic and Medchem Letters*, 8 (1), 51.
65. Kramer M S, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek J J, Reines S A, Liu G, Snively D, Wyatt-Knowles E, Hale J J, Mills S G, MacCoss M, Swain C J, Harrison T, Hill R G, Hefti F, Scolnick E M, Cascieri M A, Chicchi G G, Sadowski S, Williams A R, Hewson L, Smith D, Carlson E J, Hargreaves R J and Rupniak N M J, (1998) Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors, *Science*, 281 1640
66. Swain C J, (1998) Neurokinin Receptor Antagonists, *Progress in Medicinal Chemistry* 35, 57
67. Harper S, Bilsand J, Young L, Bristow L, Boyce S, Mason G, Rigby M, Hewson L, Smith D, O'Donnell R, O'connor D, Hill R G, Evans D, Swain C, Williams B, Hefti F. (1998) Analysis of the neurotrophic effects of GPI-1046 on neuronal survival and regeneration in culture and in vivo, *Neuroscience* 88, 1, 257
68. Smith A L, Stevenson G I, Swain C J, Castro J L, (1998) Traceless Solid Phase Synthesis of 2,3-Disubstituted Indoles, *Tet. Lett.*, 39 8317.
69. Booth S E, Jenkins P R, Swain C J, (1998) The preparation and Intramolecular Radical Cyclisation Reactions of oxime ethers, *J. Braz. Chem. Soc.* 9, 4, 389.
70. Stevenson, G I.; Huscroft, I; MacLeod, A M.; Swain, C J.; Cascieri, M A.; Chicchi, G G.; Graham, M I.; Harrison, T; Kelleher, F J.; Kurtz, M; Ladduwahetty, T; Merchant, K J.; Metzger, J M.; MacIntyre, D. E.; Sadowski, S; Sohal, B; Owens, A P. (1998) 4,4-Disubstituted Piperidine High-Affinity NK1 Antagonists: Structure-Activity Relationships and in Vivo Activity, *J. Med. Chem.* 41, 23, 4623.
71. Harrison, T. Korsgaard, M. P. G.; Swain, C. J. Cascieri, M. A. Sadowski, S. Seabrook, G. R (1998) High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a

common structural template, *Bioorg. Med. Chem. Lett.* 8, 11, 1343

72. Swain C J, Harper S, Pollack S, Smith R, Hefti F. (1998) Neurotrophic Factor Mimetics, *Rev. Exp Pharm.* 134, 281

73. Harper, S.; Bilsland, J.; Young, L.; Bristow, L.; Boyce, S.; Mason, G.; Rigby, M.; Hewson, L.; Smith, D.; O'Donnell, R.; O'Connor, D.; Hill, R. G.; Evans, D.; Swain, C.; Williams, B.; Hefti, F. (1998), Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo. *Neuroscience* 88(1), 257-267.

74. Hollingworth, G J.; Dinnell, K; Dickinson, L C.; Elliott, J M.; Kulagowski, J J.; Swain, C J.; Thomson, C G. (1999), A convenient method for the preparation of aryl cyclopropyl ethers from phenols. *Tetrahedron Lett.* 40(13), 2633-2636.

75. Seward, E. M.; Swain, C J. (1999) Neurokinin receptor antagonists. *Expert Opin. Ther. Pat.* 9(5), 571-582.

76. Swain C J, Rupniak N M J. (1999) Recent developments in Neurokinin Antagonists Annual Reports in Medicinal Chemistry

77. Harper S J; Saporito M S; Hewson L; Young L; Smith D; Rigby M; Jackson P; Curtis N; Swain C; Hefti F; Vaught J L; Sirinathsinghji D (2000) CEP-1347 increases ChAT activity in culture and promotes cholinergic neurone survival following fimbria-fornix lesion. *Neuroreport*, 11(10), 2271-6.

78. Kulagowski J J; Curtis N R; Swain C J; Williams B J. (2001) Stereocontrolled syntheses of epimeric 3-aryl-6-phenyl-1-oxa-7-azaspiro(4.5)decane NK-1 receptor antagonist precursors. *Organic Letters*, 3(5), 667-70.

79. Cooper L C; Chicchi G G; Dinnell K; Elliott J M; Hollingworth G J; Kurtz M M; Locker K L; Morrison D; Shaw D E; Tsao K L; Watt A P; Williams A R; Swain C J (2001) 2-Aryl indole NK1 receptor antagonists: optimisation of indole substitution. *Bioorganic and Medicinal Chemistry Letters*, 11(9), 1233-6.

80. Dinnell K; Chicchi G G; Dhar M J; Elliott J M; Hollingworth G J; Kurtz M M; Ridgill M P; Rycroft W; Tsao K L; Williams A R; Swain C J. (2001) 2-Aryl indole NK1 receptor antagonists: optimisation of the 2-aryl ring and the indole nitrogen substituent. *Bioorganic and Medicinal Chemistry Letters*, 11(9), 1237-40

81. Shaw D; Chicchi G G; Elliott J M; Kurtz M; Morrison D; Ridgill M P; Szeto N; Watt A P; Williams A R; Swain C J (2001) 2-Aryl indole NK(1) antagonists: optimisation of the amide substituent *Bioorganic and Medicinal Chemistry Letters*, 11(23), 3031-4.

82. Harrison T; Owens A P; Williams B J; Swain C J; Williams A; Carlson E J; Rycroft W; Tattersall F D; Cascieri M A; Chicchi G G; Sadowski S; Rupniak N M; Hargreaves R J. (2001) An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration. *Journal of Medicinal Chemistry*, 44(24), 4296-9

83. Maubach K A; Martin K; Chicchi G; Harrison T; Wheeldon A; Swain C J; Cumberbatch M J; Rupniak N M J; Seabrook G R. (2002) Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. *Neuroscience*, 109(3), 609-17.

84. Elliott J M; Castro J L; Chicchi G G; Cooper L C; Dinnell K; Hollingworth G J; Ridgill M P; Rycroft W; Kurtz M M; Shaw D E; Swain C J; Tsao K-L; Yang L. (2002) 4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists I. *Bioorganic and Medicinal Chemistry Letters*. 12(13), 1755-8

85. Cooper L C; Carlson E J; Castro J L; Chicchi G G; Dinnell K; Di Salvo J; Elliott J M; Hollingworth G J; Kurtz M M; Ridgill M P; Rycroft W; Tsao K-L; Swain C J. (2002) 4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists II. (2002) *Bioorganic and Medicinal Chemistry Letters*, 12(13), 1759-62

86. Seward E M; Carlson E; Harrison T; Haworth K R; Herbert R; Kelleher F J; Kurtz M M; Moseley J; Owen S N; Owens A P; Sadowski S J; Swain C J; Williams B J. (2002) Spirocyclic NK(1)

antagonists I: [4.5] and [5.5]-spiroketals. *Bioorganic and Medicinal Chemistry Letters*. 12(18), 2515-8

87. Conley R K; Cumberbatch M J; Mason G S; Williamson D J; Harrison T; Locker K; Swain C; Maubach K; O'Donnell R; Rigby M; Hewson L; Smith D; Rupniak N M J. (2002) Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. *Journal of Neuroscience*. 22(17), 7730-6.

88. Williams B J; Cascieri M A; Chicchi G G; Harrison T; Owens A P; Owen S N; Rupniak N M J; Tattersall D F; Williams A; Swain C J (2002) Spirocyclic NK(1) antagonists II: [4.5]-spiroethers. *Bioorganic and Medicinal Chemistry Letters*, 12(19), 2719-22.

89. Swain, C. (2003) NK1 receptor antagonists. (2002) Editor(s): King, Frank D. *Medicinal Chemistry (2nd Edition)*, 415-427. Publisher: Royal Society of Chemistry, Cambridge.

90. Rupniak, N M. J.; Carlson, E J.; Shephard, S; Bentley, G; Williams, A R.; Hill, A; Swain, C; Mills, S G.; Di Salvo, J; Kilburn, R; Cascieri, M A.; Kurtz, M M.; Tsao, K-L; Gould, S L.; Chicchi, G G. (2003) Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608., *Neuropharmacology* 45(2), 231-241.

91. Raubo, P; Kulagowski, J J.; Swain, C J. (2003) A stereoselective synthesis of (phenyl-1-oxa-7-azaspiro[4.5]-decane)s. *Synlett* (13), 2021-2024.

92. Thomson CG, Carlson E, Chicchi GG, Kulagowski JJ, Kurtz MM, Swain CJ, Tsao KL, Wheeldon A. (2006) Synthesis and structure-activity relationships of 8-azabicyclo[3.2.1]octane benzylamine NK1 antagonist, *Bioorg Med Chem Lett*. 15;16(4), 811-4 .

93. Gregory J. Hollingworth, , Emma J. Carlson, José L. Castro, Gary G. Chicchi, Natalie Clark, Laura C. Cooper, Olivier Dirat, Jerry Di Salvo, Jason M. Elliott, Ruth Kilburn, Marc M. Kurtz, Wayne Rycroft, F. David Tattersall, Kwei-Lan Tsao and Christopher J. Swain. (2006) Novel lactam NK1 antagonists with anti-emetic activity. *Bioorg and Medchem Lett* 16, 1197

94. Swain C. J., iBabel, CDK News, vol. 3, issue 1, pages 19-20

95. Christopher J. Swain, Ana Teran, Marta Maroto and Angeles Cabello (2006) Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT<sub>2A</sub> ligands. *Bioorg and Medchem Lett* 16, 6058.

96. Swain C: Open access and medicinal chemistry. *Chem Cent J*; 2007;1:2

97. Swain C J, Big Pharma in Crisis. *European Pharmaceutical Contractor* **June 2012** 12-16

98. Dr E. Zartler, Dr C. Swain & S. Pearce. Fragment library design: the evolution of fragment-based lead discovery *Drug Discovery World*, Winter 2012/13

99. P. Patrizia Mangione, Stéphanie Deroo, Stephan Ellmerich, Vittorio Bellotti, Simon Kolstoe, Stephen P. Wood, Carol V. Robinson, Martin D. Smith, Glenys A. Tennent, Robert J. Broadbridge, Claire E. Council, Joanne R. Thurston, Victoria A. Steadman, Antonio K. Vong, Christopher J. Swain, Mark B. Pepys, Graham W. Taylor Bifunctional crosslinking ligands for transthyretin. *Open Biol.* 2015 Sep;5(9):150105. doi: 10.1098/rsob.150105.

100. C. J. Swain, *Data Analysis and Visualization Tools, Reference Module in Chemistry, Molecular Sciences and Chemical Engineering*, 2016, ISBN 978-0-12-409547-2

101. Alice E. Williamson, Paul M. Ylloja, Murray N. Robertson, Yevgeniya Antonova-Koch, Vicky Avery, Jonathan B. Baell, Harikrishna Batchu, Sanjay Batra, Jeremy N. Burrows, Soumya Bhattacharyya, Felix Calderon, Susan A. Charman, Julie Clark, Benigno Crespo, Matin Dean, Stefan L. Debberty, Michael Delves, Adelaide S. M. Dennis, Frederik Deroose, Sandra Duffy, Sabine Fletcher, Guri Giaever, Irene Hallyburton, Francisco-Javier Gamo, Marinella Gebbia, R. Kiplin Guy, Zoe Hungerford, Kieran Kirk, Maria J. Lafuente-Monasterio, Anna Leen, Stephan Meister, Corey Nislow, John P. Overington, George Papadatos, Luc Patiny, James Pham, Stuart A. Ralph, Andrea Ruecker, Eileen Ryan, Christopher Southan, Kumkum Srivastava, Chris Swain, Matthew J. Tarnowski, Patrick Thomson, Peter Turner, Iain M. Wallace, Timothy N. C. Wells, Karen White, Laura White, Paul Willis, Elizabeth A. Winzeler, Sergio Wittlin, and Matthew H. Todd, *Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles*, *ACS Cent. Sci.*, 2016, 2 (10), pp 687–701

102. Jan H. Jensen , Christopher J. Swain, and Lars Olsen, Prediction of pKa Values for Druglike Molecules Using Semiempirical Quantum Chemical Methods, *J. Phys. Chem. A*, **2017**, *121* (3), pp 699–707

## Posters

Quinuclidine based NK1 Antagonists, summer Neuropeptide Conference, Martha's Vineyard, June 1993.

iBabel and ChemSpotlight, Cheminformatics Tools for Mac OS X, Apple WWDC 06, San Francisco Aug 2006

iBabel and ChemSpotlight, Cheminformatics Tools for Mac OS X, CompLife 06, Cambridge Sept 2006

## Lectures and Presentations

Drugs acting on the cholinergic neurotransmission system, Leicester University undergraduate course Nov, 1994, 1995, 1996, 1997, 1998.

Novel 5-HT<sub>3</sub> Antagonists, Trends in Receptor Research, Camerino 1991.

Substance P antagonists, Gordon Conference on Medicinal Chemistry, Colby-Sawyer College, Aug. 1994.

Neurokinin antagonists RSC-SCI, Medicinal Chemistry Summer School, Canterbury, July 1995.

Substance P antagonists, Trends in Medicinal Chemistry, London. September 1995.

Substance P antagonists, Tachykinins '95, Florence October 1995.

Neurokinin Antagonists, Sydney University Oct 1997

Neurokinin Antagonists, Tachykinins '97, Cairnes Oct 1997

Bioorganic and Medchem School, Princeton March 1997

Substance P antagonists, IRBM, July 1997

Neurokinin antagonists RSC-SCI, Medicinal Chemistry Summer School, UMIST, July 1999.

Substance P Antagonists ACS 223rd National Meeting April 2002

Neurokinin antagonists RSC-SCI, Medicinal Chemistry Summer School, Univ Nottinham, July 2003.

Neurokinin antagonists RSC-SCI, Medicinal Chemistry Summer School, Univ Nottinham, July 2005.

iBabel and ChemSpotlight, Cheminformatics Tools for Mac OS X, CompLife 06, Cambridge Sept 2006

Tricks of the Trade, RSC-SCI, Medicinal Chemistry School, Univ Nottingham 2007

Drug Distribution, RSC-SCI, Medicinal Chemistry School, Univ Nottingham 2009

Drug Distribution, RSC-SCI, Medicinal Chemistry School, Loughborough Univ 2011

A Medicinal Chemists view of Drug Discovery INSERM, Paris 2011

Open Source Malaria, Cambridge, 2015

Using Jupyter as an electronic notebook to store and share computational chemistry, March 2017 Global Health Compound Design meeting

## PATENTS

1. Kulagowski, Janusz Jozef; Swain, Christopher John; Thomson, Christopher George; Raubo, Piotr Alpoli. Preparation of spiro-azacyclic derivatives and their use as tachykinin antagonists. PCT Int. Appl. WO 9854187 A1
2. Curtis, Neil Roy; Elliott, Jason Matthew; Hollingworth, Gregory John; Jackson, Philips Stephen; Kulagowski, Janusz Jozef; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Spiro-azacyclic derivatives and their use as therapeutic agents. PCT Int. Appl., 73 pp. WO 9849170 A1 981105.
3. Harrison, Timothy; Swain, Christopher John. Preparation of 3,3-disubstituted piperidines for treating the conditions associated with an excess of tachykinins. U.S., 17 pp US 5807865 A 980915
4. Maccoss, Malcolm; Mills, Sander G.; Harrison, Timothy; Swain, Christopher John. Preparation of 5-aryl-5-heterocyclylpropylpiperidin-2-ones as modulators of chemokine receptor activity. PCT Int. Appl., 92 pp. WO 9831364 A1 980723.
5. Haworth, Karen Elizabeth; Seward, Eileen Mary; Swain, Christopher John. Preparation of azaoxaspiroalkanes and -enes as tachykinin antagonists. PCT Int. Appl., 100 pp. . WO 9813369 A1 980402.
6. Curtis, Neil Roy; Huscroft, Ian Thomas; Kulagowski, Janusz Jozef; Swain, Christopher John. Spiro-piperidine derivatives and their use as therapeutic agents. PCT Int. Appl., 103 pp. . WO 9801450 A1 980115
7. Moseley, Jonathan David; Swain, Christopher John. Spiro-ketal derivatives and their use as therapeutic agents (tachykinin antagonists). PCT Int. Appl., 92 pp. . WO 9730056 A1 970821.
8. Elliott, Jason Matthew; Kelleher, Fintan; Swain, Christopher John. Spiro-ketal derivatives and their use as therapeutic agents (tachykinin antagonists). PCT Int. Appl., 75 pp. . WO 9730055 A1 970821. CAN 127:248119
9. Baker, Raymond; Elliott, Jason; Swain, Christopher John. Preparation of tetrazole moiety-containing benzylaminopyrrolidines and benzylaminopiperidines as tachykinin receptor antagonists. PCT Int. Appl., 51 pp. . WO 9721702 A1 970619.
10. Baker, Raymond; Harrison, Timothy; Swain, Christopher John; Williams, Brian John. Spiro-piperidine derivatives and their use as tachykinin antagonists. PCT Int. Appl., 152 pp. . WO 9719084 A1 970529.
11. Swain, Christopher John; Teall, Martin Richard; Williams, Brian John. Preparation of morpholine derivatives as tachykinin antagonists. PCT Int. Appl., 70 pp. . WO 9718206 A1 970522
12. Moseley, Jonathan David; Swain, Christopher John; Williams, Brian John. Preparation of morpholine N-oxides as tachykinin antagonists. Brit. UK Pat. Appl., 63 pp. CODEN: BAXXDU. GB 2302689 A1 970129.
13. Baker, Raymond; Elliott, Jason; Stevenson, Graeme Irvine; Swain, Christopher John. Preparation of piperidine and morpholine derivatives as tachykinin antagonists. PCT Int. Appl., 66 pp. . WO 9701554 A1 970116.
14. Baker, Raymond; Elliott, Jason; Stevenson, Graeme Irvine; Swain, Christopher John. Preparation of piperidine and morpholine derivatives as tachykinin antagonists. PCT Int. Appl., 72 pp. . WO 9701553 A1 970116.
15. Harrison, Timothy; Owen, Simon Neil; Seward, Eileen Mary; Swain, Christopher John. Preparation of spiroketals as tachykinin antagonists. PCT Int. Appl., 108 pp. . WO 9620197 A1 960704. CAN 125:195668



16. Harrison, Timothy; Owens, Andrew Pate; Swain, Christopher John. Preparation of N-(aminobutynyl)morpholines as tachykinin antagonists. PCT Int. Appl., 78 pp. . WO 9605181 A1 960222.
17. Haworth, Karen Elizabeth; Teall, Martin Richard; Seward, Eileen Mary; Swain, Christopher John. Morpholine derivatives and their use as antagonists of tachykinins. PCT Int. Appl., 44 pp. . WO 9530674 A1 951116.
18. Maccoss, Malcolm; Swain, Christopher John. Preparation of aralkylamino-substituted azacyclic tachykinin antagonists. PCT Int. Appl., 49 pp. . WO 9520575 A1 950803.
19. Baker, Raymond; Harrison, Timothy; Macleod, Angus Murray; Owens, Andrew Pate; Seward, Eileen Mary; Swain, Christopher John; Teall, Martin Richard. Preparation of arylmorpholine derivatives as tachykinin antagonists. PCT Int. Appl., 148 pp. . WO 9518124 A1 950706.
20. Baker, Raymond; Macleod, Angus Murray; Seward, Eileen Mary; Swain, Christopher John. Preparation of aralkoxy and aralkylthio substituted azacyclic compounds as tachykinin antagonists. PCT Int. Appl., 46 pp. . WO 9521819 A1 950817.
21. Baker, Raymond; Swain, Christopher John; Williams, Brian John. Preparation of azacyclic tachykinin receptor antagonists. PCT Int. Appl., 51 pp. . WO 9419323 A1 940901
22. Baker, Raymond; Ladduwahetty, Tamara; Seward, Eileen Mary; Swain, Christopher John. Azacyclic tachykinin antagonists. PCT Int. Appl., 132 pp. . WO 9321181 A1 931028
23. Swain, Christopher John. Azabicyclic tachykinin receptor antagonists. Brit. UK Pat. Appl., 25 pp. CODEN: BAXXDU. GB 2268931 A1 940126.
24. Seward, Eileen Mary; Swain, Christopher John. Preparation of azacyclic compounds as tachykinin antagonists. PCT Int. Appl., 54 pp. . WO 9402461 A1 940203.
25. Swain, Christopher John. Azatricyclic tachykinin antagonists. Brit. UK Pat. Appl., 23 pp. CODEN: BAXXDU. GB 2269170 A1 940202.
26. Ladduwahetty, Tamara; Swain, Christopher J. Azabicyclic compounds as tachykinin antagonists. Eur. Pat. Appl., 21 pp. CODEN: EPXXDW. EP 536817 A1 930414.
27. Baker, Raymond; Harrison, Timothy; Swain, Christopher J.; Williams, Brian J. Preparation of 3-benzyloxy-2-phenylpiperidines and analogs as tachykinin antagonists. Eur. Pat. Appl., 38 pp. CODEN: EPXXDW. EP 528495 A1 930224.
28. Baker, Raymond; MacLeod, Angus Murray; Merchant, Kevin John; Swain, Christopher John. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy. PCT Int. Appl., 83 pp. WO 9301169 A2 930121. CAN 119:117105
29. Baker, Raymond; Swain, Christopher J.; Teall, Martin R.; Williams, Brian J. Preparation of benzyloxyazabicycloalkanes as tachykinin antagonists. Eur. Pat. Appl., 16 pp. CODEN: EPXXDW. EP 520555 A1 921230.
30. Swain, Christopher J.; Teall, Martin R.; Williams, Brian J. Preparation of 2-amino-1-benzyloxy-3,3-diphenylpropanes and analogs as tachykinin antagonists. Eur. Pat. Appl., 39 pp. CODEN: EPXXDW. EP 522808 A2 930113.
31. Baker, Raymond; Swain, Christopher; Seward, Eileen M. Preparation of benzyloxyazabicycloalkanes as tachykinin antagonists. Eur. Pat. Appl., 26 pp. CODEN: EPXXDW. EP 499313 A1 920819.
32. Baker, Raymond; Swain, Christopher; Saunders, John. Preparation and formulation of indolyl(imidazolylalkyl)oxazoles, -oxadiazoles, and analogs as S3 antagonists. U.S., 11 pp. CODEN: USXXAM. US 5140034 A 920818.
33. Baker, Raymond; Kneen, Clare O.; Saunders, John; Swain, Christopher. Preparation of spirocyclic compounds incorporating five-membered rings with two heteroatoms, especially spiro[azabicyclooctanoxazoles], useful as drugs. Eur. Pat. Appl., 38 pp. CODEN: EPXXDW.

34. Owen, Simon Neil; Swain, Christopher John; Williams, Brian John. Preparation of 2(R)-[1-[3,5-bis(trifluoromethyl)phenyl]-2(S)-hydroxyethoxy]-3(S)-(4-fluorophenyl)-4-[(1-methyl-1,2,4-triazol-3-yl)methyl]morpholine for treatment of pain, inflammation, migraine, emesis, postherpetic neuralgia, depression, or anxiety. U.S. (1999), 9 pp
35. Baker, Raymond; Curtis, Neil Roy; Elliott, Jason Matthew; Harrison, Timothy; Hollingworth, Gregory John; Jackson, Philip Stephen; Kulagowski, Janusz Jozef; Rupniak, Nadia Melanie; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety. U.S. (2000), 14 pp.
36. Baker, Raymond; Curtis, Neil Roy; Elliott, Jason Matthew; Harrison, Timothy; Hollingworth, Gregory John; Jackson, Philip Stephen; Kulagowski, Janusz Jozef; Rupniak, Nadia Melanie; Seward, Eileen May; Swain, Christopher John; Williams, Brian John. Use of NK-1 receptor antagonists for treating schizophrenic disorders. U.S. (2000), 14 pp., Cont.-in-part of U.S. Ser. No. 980,930,
37. Owen, Simon Neil; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Preparation of novel substituted tetrahydropyrans as neurokinin 1 (NK-1) receptor antagonists. PCT Int. Appl. (2000), 149 pp
38. Castro Pineiro, Jose Luis; Dinnell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John; Shaw, Duncan Edward; Swain, Christopher John. Synthesis of aryl-amido-cyclohexane derivatives and their use as NK-1 receptor antagonists. PCT Int. Appl. (2001), 199 pp. CODEN: PIXXD2 WO 2001087838 A1
39. MacLeod, Angus Murray; Swain, Christopher John; Van Niel, Monique Bodil. Preparation of 1-piperidinylpropan-2-ols as antidepressants and anxiolytics. Brit. UK Pat. Appl. (2000), 56 pp. CODEN: BAXXDU GB 2347423
40. Owen, Simon Neil; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Preparation of 2-pyranyl ethers as NK1 receptor antagonists. PCT Int. Appl. (2000), 43 pp. CODEN: PIXXD2 WO 2000056728
41. Castro Pineiro, Jose Luis; Dinnell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John; Shaw, Duncan Edward; Swain, Christopher John. Preparation of cyclohexane derivatives for therapeutic use in the treatment of disorders, such as depression, anxiety, pain, inflammation, migraine, and vomiting. PCT Int. Appl. (2001), 153 pp. CODEN: PIXXD2 WO 2001087866 A
42. Baker, Raymond; Saunders, John; Swain, Christopher. Five-membered heterocycles as pharmaceuticals. Eur. Pat. Appl., 39 pp. CODEN: EPXXDW. EP 328200 A1 890816 Castro Pineiro, Jose Luis; Owen, Simon Neil; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Preparation of difluorophenyltetrahydropyran derivatives as nk-1 receptor antagonists. PCT Int. Appl. (2002), 30 pp. CODEN: PIXXD2 WO 2002016343 A1
43. Castro Pineiro, Jose Luis; Owen, Simon Neil; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Preparation of tetrahydropyran derivatives as nk-1 receptor antagonists. PCT Int. Appl. (2002), 51 pp. CODEN: PIXXD2 WO 2002016344 A1 20020228
44. Owen, Simon Neil; Swain, Christopher John; Williams, Brian John. Arylmethoxytetrahydrofuran derivatives and their use as NK-1 antagonists. PCT Int. Appl. (2002), 54 pp. CODEN: PIXXD2 WO 2002024673 A1
45. Castro Pineiro, Jose Luis; Raubo, Piotr Antoni; Swain, Christopher John. Preparation of [(phenylethoxy)tetrahydropyranyl]piperidinecarboxylates and analogs as neurokinin NK-1 receptor antagonists. PCT Int. Appl. (2002), 69 pp.
46. Castro Pineiro, Jose Luis; Dinnell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John; Shaw, Duncan Edward; Swain, Christopher John. Preparation of gem-disubstituted cyclohexane-containing azetidinones, pyrrolidinones and piperidinones as neurokinin 1 receptor antagonists and their use as therapeutic agents. PCT Int. Appl. (2002), 58 pp. CODEN:

PIXXD2 WO 2002102372 A1 20021227

47. Dirat, Olivier; Elliott, Jason Matthew; Huscroft, Ian Thomas; Jelley, Richard Alexander; Kulagowski, Janusz Jozef; Raubo, Piotr Antoni; Shaw, Duncan Edward; Sternfeld, Francine; Swain, Christopher John. Preparation of phenylethoxytetrahydropyranylmethyloxaazaspirodecanes and related compounds as tachykinin antagonists. PCT Int. Appl. (2004), 140 pp.

Updated January 2017